enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Prostate cancer - Wikipedia

   en.wikipedia.org/wiki/Prostate_cancer

   Prostate cancer is the most diagnosed cancer in men in over half of the world's countries, and the leading cause of cancer death in men in around a quarter of countries. [ 91 ] Prostate cancer is rare in those under 40 years old, [ 92 ] and most cases occur in those over 60 years, [ 2 ] with the average person diagnosed at 67. [ 93 ]

3. Study says prostate cancer rates expected to double worldwide ...

   www.aol.com/study-says-prostate-cancer-rates...

   The report also predicts prostate cancer deaths will climb to almost 700,000 globally by 2040 — mainly among men in low-and middle-income countries. ... The latest World Health Organization data ...

4. Seviteronel - Wikipedia

   en.wikipedia.org/wiki/Seviteronel

   Seviteronel is a nonsteroidal antiandrogen, acting specifically as an androgen synthesis inhibitor via inhibition of the enzyme CYP17A1, for the treatment of castration-resistant prostate cancer.

5. Enzalutamide - Wikipedia

   en.wikipedia.org/wiki/Enzalutamide

   Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. [2] [9] It is indicated for use in conjunction with castration in the treatment of metastatic castration-resistant prostate cancer (mCRPC), [2] nonmetastatic castration-resistant prostate cancer, [2] and metastatic castration-sensitive prostate ...

6. Medical uses of bicalutamide - Wikipedia

   en.wikipedia.org/wiki/Medical_uses_of_bicalutamide

   Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. [1] It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), [2] [3] and as a monotherapy at a dosage of 150 mg/day ...

7. DU145 - Wikipedia

   en.wikipedia.org/wiki/DU145

   Castration-resistant prostate cancer (CRPC) is prostate cancer that progresses despite extremely low testosterone in the body often due to medical castration. [4] Unlike many other types of prostate cancer, CRPC do not need normal testosterone levels, but they still require regular androgen receptors (AR).